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Abstract
Background: Cutaneous Leishmaniasis (CL) is a skin infection prevalent in more than 70 countries worldwide. CL can lead to 
permanent scars and disfigurement. Treatments are costly, hazardous, and with limited effectiveness. 
Methods: We searched databases up to October 17, 2017. All randomized controlled clinical trials (RCTs), performed on people living 
in endemic regions, with no previous history of leishmaniasis of any type, in which Leishmania vaccination was done against placebo 
or other active preventative means, in order to prevent cutaneous leishmaniasis (CL) were included. Two authors independently 
screened titles, abstracts, and full texts; extracted data; and assessed risk of bias.
Results: We included 12 trials (nine published, three unpublished) with 28,297 randomised participants. Studies were conducted in 
endemic populations from Brazil, Colombia, Ecuador and Iran. There was no significant difference between any dose of vaccine versus no 
Leishmaniasis vaccination in the pooled analysis of trials of Old World and American cutaneous leishmaniasis, after one year follow up 
(RR=0.87, 95% CI 0.73 to 1.05; 22,566 participants; 11 studies, NNT = 355), or after two years follow up (RR=0.88, 95% CI 0.70 to 1.11; 
13,168 participants; 6 studies, NNT = 155). Pooled analysis was not done for 3 studies with more than two years follow up, because the 
heterogeneity was high. The exact number of these side effects were trivial or not reported. No study measured mortality or quality of life. 
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• The vaccine had no significant effect in preventing CL after one year follow-up.
• The vaccine had no significant effect in preventing CL after two years follow-up either.
• There was no evidence about the impact of different doses in preventing CL.
• Side effects were trivial or not reported.
Highlights: 
Conclusion: The results of this review show that there is no significant difference in the occurrence of cutaneous leishmaniasis after 
one or two years follow-up between people who were given any dose of the first generation leishmaniasis vaccine and those that were 
not given the vaccine. More investigation about these vaccines should be done.
Background 
Leishmaniasis is caused by a parasite belonging to the genus Leishmania, which is spread by the bite of the female sandfly 
(Phlebotomine). Leishmaniasis is best considered as a spectrum of diseases with distinctive manifestations ranging from infections 
without symptoms and mild self-healing cutaneous (skin) disease to severe non-healing diffuse cutaneous and lethal visceral 
leishmaniasis [1].
The disease is geographically and ecologically widespread, occurring in tropical and subtropical regions on all continents except 
Australia [2]. Cutaneous leishmaniasis (CL) is endemic in more than 70 countries worldwide [3]. There are 1.5 to 2.0 million new 
cases of leishmaniasis per year worldwide, of which 400,000 to 500,000 are visceral (90% of them in Bangladesh, Brazil, India, 
Nepal and Sudan) and 1,000,000 to 1,500,000 cutaneous (90% of them in Afghanistan, Algeria, Brazil, Iran, Peru, Saudi Arabia and 
Sudan) [4-6]. With a prevalence of 12 to 14 million cases (and a world population of 350 million at risk [7], leishmaniasis is a health 
problem in 88 countries, especially in lower and middle income economies [4,8]. It is likely that the number of cases occurring 
Description of the condition
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around the world is considerably greater than that officially reported. One reason for this is under-reporting by affected people 
who are not accessing or seeking medical or diagnostic facilities [7]. In several areas of the world, there is a clear increase in the 
number of cases, e.g. Brazil, Kabul (Afghanistan) and Ouagadougou (Burkina Faso) [7], and many endemic areas have reported a 5 
times increase over a period of seven years [2]. Such increases can be explained in part by improved diagnosis and case notification, 
but are also a result of inadequate vector or reservoir control, increased detection of cutaneous leishmaniasis associated with 
opportunistic infections (e.g. HIV/AIDS), and the emergence of anti-leishmanial drug resistance [3]. Also, reporting of the disease 
is compulsory in only one-third (33 out of 88) of the endemic countries [5].
Cutaneous leishmaniasis, the most common form and therefore the main focus of this review, includes zoonotic cutaneous 
leishmaniasis (ZCL) where the reservoir is a non-human mammal and anthroponotic CL where the reservoir is human. Cutaneous 
leishmaniasis can show at least three clinical forms including acute cutaneous leishmaniasis (ACL), chronic cutaneous leishmaniasis 
(CCL) and occasionally leishmaniasis recidivans (LR) [9]. In 2-5% of cases, acute cutaneous leishmaniasis becomes chronic or can 
develop into leishmaniasis recidivans, where the persistent presence of parasites may drive a skin reaction around the original 
primary lesion long after healing [10]. Leishmaniasis recidivans is difficult to treat and leaves extensive scars [5].
Cutaneous leishmaniasis usually produces skin ulcers on the exposed parts of the body such as the arms, legs and especially the 
face [11]. Over 90% of cases of cutaneous leishmaniasis heal spontaneously within 3-18 months [8].
Causes and Natural History: The leishmaniases are caused by 20 species of parasites belonging to the genus Leishmania, which 
are pathogenic for humans. The protozoa are transmitted by the bite of a tiny two to three millimetre-long insect vector, the 
Phlebotomine sandfly in the Old World [11], and Lutzomyia sandfly in the New World [12]. Approximately 30 sandfly species 
are proven vectors [7] with more than 40 additional species probably involved in transmission [3]. These sandflies are able to pass 
through the usual netting used for mosquitoes. Sandflies are found around human habitations and breed in specific organic wastes 
such as faeces, manure, rodent burrows and leaf litter [12]. When a sandfly bites an infected animal or human it becomes infected; 
the parasitic organisms are then passed on when the sandfly bites its next victim [7,11]. Humans are usually accidental hosts of 
these flies; natural hosts include a variety of small mammals, and dogs [2].
A striking difference occurs between the so-called Old World (i.e. Africa, Europe, and Asia) and New World (i.e. the Americas) 
cutaneous leishmaniases in the ecological context of their respective transmission cycles. Old World cutaneous leishmaniasis 
usually occurs in open semi-arid or even desert conditions, but New World cutaneous leishmaniasis is still mostly associated with 
forests [3]. Each species of Leishmania favours one or more animal reservoirs, except Leishmania donovani [13] and Leishmania 
tropica [5] in which the reservoir is human.
The Leishmania parasite has two different life cycle forms called promastigote (with flagellum which is the means by which it 
moves) and amastigote (without flagellum). Parasites, in the form of amastigotes are taken up from the infected tissues or blood 
of a mammalian host during feeding by female sandflies. Within the midgut of the sandflies, the parasites undergo a change to the 
promastigote form and multiply. Once the promastigotes are fully developed, they migrate from the gut to the sandfly pharynx 
and proboscis (the insect’s tubular feeding organ), where they remain until they are injected into a new mammalian host during a 
subsequent blood meal. Between 10 to 200 (or even up to 1000) promastigotes enter the skin during each feeding by an infected 
sandfly. Some of the promastigotes are taken up by the macrophage cells (cells related to the immune system) in the host skin. 
Within the macrophages the promastigotes transform into amastigotes. When a macrophage becomes filled with amastigotes the 
macrophage is disrupted. The amastigotes re-enter the extracellular space and are then taken up again by other macrophages [13]. 
However, ulceration and tissue destruction in CL has been proposed to be a result of immune activation evoked by the infection 
rather than a direct effect of the infectious burden of parasites into the skin [14]. The incubation period of CL is usually measured 
in months, but ranges from a few days (about 15 days) to over a year [15]. The disease begins as a small red swelling (papule) at 
the site of the sandfly bite. The papule increases in size and becomes a nodule which eventually ulcerates and crusts over. The ulcer 
is typically painless unless there is secondary bacterial or fungal infection [12]. Sometimes, the ulcer is associated with bleeding 
and itching. Many people think that covering the ulcer delays its healing, and allow it to be exposed to the air. However, this may 
facilitate transmission of leishmaniasis to others [10]. Usually, these scars do not disappear. They stay forever [16]. 
Impact: A total of 11.8% of total worldwide DALYs (Disability Adjusted Life Years) is associated with all the leishmaniases that 
occur in the eastern Mediterranean countries, where CL is concentrated [10].
There is a social stigma associated with the deformities and disfiguring scars caused by this disease that keeps affected people hidden. 
Victims are mostly children in endemic areas, and lesions are frequently on the face. The disfigurement caused by CL scars lead to 
stigma, social isolation, suffering and may be a barrier to marriage, especially for girls and young women [10]. New World CL, which 
Clinical Forms: Clinical forms of leishmaniasis are diverse, representing a complex of diseases: visceral leishmaniasis (VL) which 
affects internal organs and can be fatal; post kala-azar dermal leishmaniasis (PKDL), which arises after visceral infection [6]; 
muco-cutaneous leishmaniasis (MCL), which is a mutilating disease affecting mucous membranes; diffuse cutaneous leishmaniasis 
(DCL), which is a long-lasting disease due to a deficient cellular mediated immune response; and cutaneous leishmaniasis (CL), 
which is confined to the skin and can be disfiguring [7].
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is endemic in most countries of Latin America, has a serious sequel, which is mucosal or mucocutaneous leishmaniasis (ML). Unless 
diagnosed and treated early, this disease can progress to destroy tissues in the nose, mouth and throat and in some cases leads to 
death. Many suicides or attempts at suicide have been recorded due to the stigma associated with ML in Latin America [10].
Cutaneous leishmaniasis also creates a burden on the national economy. Seventy-seven percent of men in Ecuador believe CL 
diminishes their ability to work. The cost of treatment is high and is in most cases beyond the financial means of affected people 
who are mostly poor [10]. On several occasions, epidemics have significantly delayed the implementation of land development 
projects [11]. Leishmaniasis has thus become a disease that impedes socioeconomic development.
Diagnosis: For people in endemic areas, or where travellers return from endemic areas, the clinical diagnosis of typical nodules 
or sores is not difficult. Deeper sores from beneath the skin, sores arising from lymphatic spread or chronic sores in which 
scarring predominates may present diagnostic difficulties. Confirmation of diagnosis is through microscopic demonstration of 
the parasite [15].
Samples are taken by scraping the affected sore [12]; punch biopsy with tissue impression smears [12]; or needle aspiration of 
tissue fluid from the margin of the lesion [12].
The parasite is identified by staining with Giemsa and looking under the microscope; cultivating Leishmania species in specific 
culture media (such as Novy-MacNeal-Nicolle (NNN) medium, etc); inoculating suspected specimens into susceptible laboratory 
animals (such as hamsters) [13,15]; or using the highly sensitive polymerase chain reaction test [12].
The leishmanin skin test (LST) is considered as a simple indicator for cell mediated immunity; a delayed hypersensitivity reaction 
to intradermal crude Leishmania antigen is produced in healing or cured cases of both cutaneous and visceral leishmaniasis [17]. 
It is a highly specific test and is of great value in epidemiological studies, although it has little clinical use [18]. The leishmanin 
skin test can be used for epidemiologic surveys, diagnosis in nonendemic areas particularly in recidivans and mucosal forms of 
CL and for identification of chronic forms of CL [9].
Treatment: Most leishmaniasis sores will eventually heal spontaneously, but the duration of this process cannot be predicted 
in an individual case. Topical methods of treatment such as heating, freezing and ointments are used for simple sores. Systemic 
treatments including antimonials [19,20], amphotericin B, miltefosine and paromomycin can be used for more problematic 
sores. However, some are expensive, some may be toxic, and, when used as monotherapy, may promote the development of drug 
resistance. Therefore, the WHO has suggested using drug combinations. Recently authors have suggested immunochemotherapy, 
whereby a low-dose or short course of an effective drug is prescribed with an injection of a vaccine or immunomodulator to induce 
an effective immune response [21].
After healing, individuals are usually immune to reinfection from the same species, although secondary sores in old age or due to 
a parasite of a different kind have been reported [15].
There are reports that show in immunocompromised hosts the disease may return upon stopping treatment, and even in ‘cured’ or 
asymptomatically infected individuals, fulminating disease appears after immunosuppression or HIV infection [21].
Prevention and Control: Controlling the sandflies, which transmit the disease (vector control), in and around the home consists of the 
use of insecticides (usually pyrethroids) being sprayed around the house or individual protection based on pyrethroid-impregnated 
bed nets [7]. Various repellents, such as dimethyl-phthalate and imidacloprid/permethrin are also used by people to discourage insect 
bites [22, 23]. Animal reservoir control for CL is based on the use of poisoning baits and environmental management to control 
rodents [7]. More details about vector and reservoir interventions to prevent CL can be found in references [24].
The complex epidemiological characteristics of the disease and its transmission have limited the success of these disease control 
efforts. Vector and reservoir control are not always possible or practical in the case of zoonotic diseases, or require infrastructure 
beyond the means of the affected population. Even if successful, these measures are not maintained because of the cost [11,25] and 
are short lived [8].
Leishmaniasis is thought to be one of a few parasitic diseases likely to be controllable by vaccination. The relatively uncomplicated 
Leishmania life cycle and the fact that recovery from infection usually renders the host resistant to subsequent infection indicate that 
a successful vaccine is feasible. Evidence from studies in animal models indicates that protection can be achieved by immunisation 
with protein or DNA vaccines [26].
The History of the Vaccine: Vaccination through artificial inoculation of live parasites (leishmanisation) has been used to induce 
protection in the past. Leishmanisation was used in Iran in the 1980s and in Israel in the 1970s as prophylaxis against leishmaniasis, but 
is not currently practiced in either country [27]. Though reported to be efficacious in some studies, leishmanisation was abandoned 
for ethical reasons due to its severe side effects such as chronic non-healing lesions [28]. Further problems were the rising incidence 
of HIV and the use of immunosuppressive agents, parasite persistence in the body and difficulties with the inoculum control [29]. 
Description of the intervention 
Annex Publishers | www.annexpublishers.com                    
 
Volume 1 | Issue 1
Journal of Vaccines & Vaccination Studies 
 
4
However, this old method has been studied again recently [30]. Researchers have also recently used deep-frozen Leishmaniamajor 
(L. major) promastigotes (the parasite or its components) for immunisation against leishmaniasis according to the World Health 
Organization (WHO) protocol in Geneva, 1997 [31].
Leishmania are easily cultured, hence the production of vaccines using the parasite or its components are feasible [50]. In addition, 
for the past few decades, killed parasites have been used as skin test antigens for diagnosis of leishmaniasis in people. These killed 
parasites have also been used with or without adjuvants as vaccines or for immunotherapy in clinical studies [51].
Some evidence from experimental, clinical and field studies suggested that anti-Leishmania vaccines based on killed whole, 
fractionated or recombinant parasite promastigotes are safe and capable of inducing immunity to leishmaniasis [51,52].
However, those producing a suitable human vaccine have to consider some practical issues. For example, the vaccine should be 
delivered as a single, defined molecule to facilitate compliance with regulatory and manufacturing standards and to lower the overall 
production costs. Ideally, the vaccine should protect against cutaneous as well as visceral leishmaniasis [26].
At present there is only one prophylactic live vaccine for use in human populations [29]. This is a mixture of live virulent Leishmania 
major mixed with killed parasite registered in Uzbekistan [53]. However, there is no registered prophylactic leishmaniasis vaccine 
against any form of human leishmaniasis [54,55], although three licensed vaccines have been developed for dogs [54].
The Different types of vaccines up to now and their characteristics: Leishmaniasis is a complex disease caused by several different 
species of parasite that are closely related, so if a single vaccine could be developed there is the possibility that it could protect against 
several diseases [54]. An ideal Leishmaniasis vaccine should be safe and cost effective, consist of defined components capable of 
large scale production, contain antigens that are shared among multiple species, induce relevant long-lived T cell responses, protect 
against infection and disease and be effective for both prophylactic and therapeutic indications [54]. Drug resistance, toxicity and 
the side effects of expensive chemotherapeutics and difficult reservoir control emphasize the need for a safe and effective vaccine, 
which is not available yet [56].
Up to the present, three generations of vaccines have been reported for leishmaniasis. The first generation candidate vaccines against 
leishmaniasis were prepared using inactivated or killed whole parasites as their main ingredient, and were considered useful due 
to their relative ease of production and low cost. These vaccines have been the subject of many investigations over several decades 
and are the only leishmaniasis vaccines which have undergone phase 3 clinical trial evaluation. However, although studies have 
demonstrated the safety of the vaccines and some studies showed immunogenicity and some indication of protection, they generally 
have poor efficacy [27,29]. 
The second generation vaccines have been used since the 1990s, and use live genetically modified parasites, or bacteria or viruses 
containing Leishmania genes, but their success in field trials has not yet been reported. Authors predict that the second generation 
of leishmaniasis vaccines with native antigens and effective adjuvants are likely to be licensed and used in control programs in the 
coming 25 years [29].
The third generation vaccines are the multiple-gene DNA vaccines that are stable and do not require refrigerated transportation. 
They include genes coded for a protective antigen, cloned into a vector containing a eukaryotic promoter [29]. The DNA vaccine 
against leishmaniasis was successfully tested for immunogenicity and protective effects, in the rodent models of leishmaniasis 
infection [57] and might be used for prevention in humans in the future. Some authors have also suggested that the saliva of 
leishmania-transmitting vectors can be a valuable candidate for developing anti-Leishmania vaccines [58].
How the intervention might work?: The manufacture of this vaccine like many other vaccines was based on observations that after 
leishmaniasis lesions heal and leaves scars, the human immune system develops resistance to this micro-organism, and reinfection 
is less likely. Therefore, The cultivated or killed parasite or parasite parts were used for making the vaccine [16].
In this review, we focus on the first generation of vaccines.
Also, attention has been turned to the use of killed [9,32-42] or attenuated [43] parasite vaccines and defined subunit vaccines [44-49].
Although leishmaniasis has a high incidence, it is a neglected disease and more research is needed for its control. The disease varies 
in severity and can lead to severe permanent mutilation in thousands of people every year around the world, with repercussions for 
public health and has an impact on the productivity of many countries. Existing treatments are expensive, associated with adverse 
effects, and of fairly low efficacy [7]. Cochrane systematic reviews of treatments for leishmaniasis have been performed [19,20]; 
however, they showed a lack of evidence for potentially beneficial treatments.
The main challenge for leishmaniasis control is to translate new knowledge into control tools [7]. Consequently, a safe, efficacious, 
and affordable vaccine could be the most practical and cost-effective control tool to prevent disease in many situations [59].
Why it is important to do this review 
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Types of studies 
Types of participants 
Types of interventions 
All randomized controlled clinical trials (RCTs).
People living in endemic regions, with no previous history of leishmaniasis of any type.
Leishmania vaccination against placebo or other active preventative means. We also considered trials not using any form of 
treatment in the control arm.
We included all types of first generation vaccines, such as: live (Leishmanization); attenuated; killed (by Merthiolate, heat, freeze-
thaw, etc.); fractionated (fractions 5, 9, 6, etc.); purified or recombinant parasite antigens (Gp63, cysteine proteinases, etc.); and 
other molecular or DNA vaccines (IL-12, LPG, heat shock protein, etc).
The predefined exclusion criteria for articles under review were:
• The occurrence rate of cutaneous leishmaniasis not reported; i.e. RCTs which look at immunological response to the leishmaniasis 
   vaccine, but did not report the occurrence of CL were excluded, even if they presented information about side effects, mortality 
   or quality of life.
• articles about human leishmaniasis but not including the cutaneous form;
• articles about using the vaccine for treatment of cutaneous leishmaniasis after its presence and not about prevention
• studies including environmental manipulation and not vaccines;
• Studies on animals not humans.
Types of outcome measures
Primary outcomes 
Secondary outcomes 
1. Occurrence of cutaneous leishmaniasis at the end of one year, two years and more than two years.
1. Leishmanin skin test conversion rate (LST) at the end of one year, two years and greater than two years. Mild skin test reactions 
    (indurations <5mm were regarded as negative and >5mm as positive).
2. Side effects of the vaccine, including:
    o local side effects, such as pain, redness, ulcer, lymph node swelling, itching and induration;
    o mortality;
    o quality of life.
We did not consider other immunological or physiological predictors of immunity. These predictors include changes in the levels 
of interferons, interleukins or cytokines and the lymphocyte proliferation rates. These measures try to indirectly predict immunity 
to disease and may not be as reliable as the actual disease occurrence rate or LST conversion rate.
We aimed to identify all relevant randomised controlled trials (RCTs) regardless of language or publication status (published, 
unpublished, and in progress).
Electronic searches: We searched the following databases up to 17 October 2017. Details are in the appendix. The Cochrane Skin 
Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL); 2016, Issue 9, in the Cochrane Library, 
MEDLINE via Ovid (from 1946), Embase via Ovid (from 1974); and LILACS (Latin American and Caribbean Health Science 
Information database, from 1982), Persian Databases at SID (Scientific Information Database of Iran, www.sid.ir), Conference 
Papers Index, Health and Medical Complete via Proquest, Web of Knowledge/ Web of Science; and General search engines and 
meta-search engines(google, alta vista, excite, search, dogpile, metacrawler), using a search strategy similar to the terms used for 
searching the Cochrane Skin Group’s Specialised Register.
Criteria for considering studies for this review 
Search methods for identification of studies
This systematic review seeks to evaluate vaccination as a means of preventing leishmaniasis.
The plans for this review were published as a protocol ‘Vaccines for preventing cutaneous leishmaniasis’ [60].
To assess the effects of vaccines to prevent cutaneous leishmaniasis.
Objectives 
Methods 
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Selection of studies: Two authors (NK and AK) independently screened all references identified through the search and checked 
the reference list of the relevant clinical trials and review papers, and also contacted the trial authors of the published papers to 
retrieve unpublished data. Two authors (UG and AK) contacted trial authors in the field of leishmaniasis in different countries to 
retrieve any additional unpublished articles. Papers matching the inclusion criteria were chosen by NK and AK. We solved any 
differences of opinion through discussion with the review team. We did not attempt to blind the review authors to the authorship 
information of the trials during study selection or data extraction.
Data extraction and management: We (NK and AK or UG) put the data that was independently extracted onto data summary 
forms and sent the final extracted data sheets for review to other members of the review team and discussed ambiguous areas 
through email. If there was uncertainty, we contacted trial authors for clarification. Where included trials were conducted by 
authors of this review, data extraction was performed by other co-reviewers (NK and UG) who were not involved in the trial.
We described each of the necessary components for each trial and its risk of bias in the Characteristics of included studies table. 
We also extracted the information mentioned below in our information sheets.
• What type of method was used for the RCT?
• How many, or what percentages of participants, were lost to follow-up in each arm of the study?
• Were the participants analyzed in the groups that they were originally randomized (Intention-to-treat analysis)?
• Was a sample-size calculation mentioned?
• Were the study groups similar at baseline (e.g. for age, sex, location of residence and etc.)?
• Were the inclusion and exclusion criteria of the population specified? How representative was the study population of a real 
   endemic population?
• What was the intervention in the control group? A placebo or nothing?
• Were additional therapeutics used, (such as BCG)? If additional therapeutics were used, were they used identically in both arms?
• Was the outcome (developing cutaneous leishmaniasis) confirmed by pathology or lab results?
• What was the source of funding for the trial? Is it likely to have affected the results of the trial?
Assessment of risk of bias in included studies: We (NK, UG and AK) assessed the risk of bias of the selected studies independently 
using The Cochrane Collaboration’s tool for assessing risk of bias as described in Chapter 8, section 8.5, in the Cochrane Handbook 
for Systematic Reviews of Interventions [61]. With this tool, we assessed the risk of bias as ‘low’, ‘high’ or ‘unclear’ for each of the 
following domains:
• The method of generation of the random sequence. The satisfactory method of generating the allocation sequence had to be 
   unpredictable (selection bias);
• The method of allocation concealment. It was considered “adequate” if the assignment could not be foreseen (selection bias);
• Blinding of participants and personnel (performance bias);
• Blinding of outcome assessment (detection bias);
• Incomplete outcome data (attrition bias);
• Selective reporting (reporting bias)
• Other bias
Data collection and analysis 
We searched the following trials registers up to 17 October 2017, using a search strategy similar to the terms used for searching the 
Cochrane Skin Group’s Specialised Register:
The World Health Organization International Clinical Trials Registry platform (ICTRP) (www.who.int/trialsearch); the Ongoing 
Skin Trials Register (www.nottingham.ac.uk/ongoingskintrials); ClinicalTrials.gov (www.clinicaltrials.gov); the ISRCTN registry 
(www.isrctn.com/); the Australian and New Zealand Clinical Trials Registry (www.anzctr.org.au); and Trials Central (www.
trialscentral.org).
We checked the bibliographies of included studies and some reviews for further references to relevant trials.
We contacted the leading authors of leishmaniasis studies to see if they were aware of any recent or ongoing research, or any 
unpublished data. We also contacted the following Tropical Medicine Centres:
Department of Infectious Diseases and Tropical Medicine at the University of Munich, Germany; Swiss Tropical Institute, 
Switzerland; Prince Leopold Institute of Tropical Medicine, Belgium; McGill Centre for Tropical Disease, Canada; Tulane University 
School of Public Health & Tropical Medicine, USA; London School of Hygiene & Tropical Medicine, UK; Tropical Medicine at 
the Liverpool School of Tropical Medicine, UK; Department of Public Health and Tropical Medicine, James Cook University, 
Australia; Institut Pasteur, France; Bernhard Nocht Institute, Germany; Trop Ed Europ, Spain; Centro Dermatologico Federico 
Lleras Acosta, Colombia; Skin disease & Leishmaniasis Research Centre, Kerman & Tehran, Iran; and Center for Research and 
Training in Skin Diseases and Leprosy, School of Public Health, Tehran Medical University, Iran. We did not perform a separate 
search for adverse effects of vaccines for preventing cutaneous leishmaniasis. Instead we examined data on adverse effects reported 
in our included studies.
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Sensitivity analysis: We planned to conduct sensitivity analyses to examine the effects of excluding poor-quality studies, defined 
as those with a moderate or high risk of bias as described in the Cochrane Handbook for Systematic Reviews of Interventions [61]; 
however there were insufficient studies to be able to perform these analyses.
Summary of findings tables were created for all main comparisons, including the primary and key secondary outcomes. The 
quality of evidence was evaluated with the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) 
working group grades of evidence. 
For a complete description of studies see Appendix.
Data synthesis: For studies with a similar type of active intervention, a meta-analysis was performed to calculate a weighted 
preventive effect across trials using a random effects model. Statistical heterogeneity was assessed using I2. Data was synthesised 
using meta-analysis techniques, if I2 was less than 80%. Where it was not possible to perform a meta-analysis, the data were 
summarised for each trial.
We presented the efficacy of three-dose, two-dose and one-dose regimens in separate meta-analyses.
Subgroup analysis and investigation of heterogeneity: We planned to explore further reasons for heterogeneity, if substantial 
heterogeneity (I2 statistic > 50%) existed between studies for the primary outcome. However, due to a lack of sufficient studies, 
and because generally the level of heterogeneity between the studies was relatively low, we did not conduct any subgroup analyses.
Description of studies 
Measures of treatment effect: For dichotomous outcomes, we estimated pooled risk ratios (RR) with 95% confidence intervals 
(CI), and expressed as number needed to treat to benefit from prevention (NNT), where appropriate. For the primary outcomes, 
data were categorised into one, two and greater than two years. For the latter time point, end points more than two years were used 
to capture longer term benefits. Side effects were described qualitatively. 
In future studies, if we encounter continuous outcomes, we will estimate difference in means (MD) with 95% CI, or as standardised 
mean differences (SMD) if comparable scales have been used.
Unit of analysis issues: Where there were multiple intervention groups within a trial, pair-wise comparisons were made of similar 
active interventions versus no treatment, placebo, or another active intervention. Because vaccination is designed to have long term 
effects, cross-over trials would have been analysed using data from the first phase only and pooled, where possible, with parallel 
design studies. Internally controlled trials would have been excluded from the analysis as they were not an appropriate method to 
use for this research question. Cluster randomised trials would have ideally been analysed taking intracluster coefficients (ICC) into 
account. If this information was not presented in the included study, we could not adjust the standard error to reflect the design.
Dealing with missing data: We conducted an intention-to-treat analysis. If possible, authors of studies would be contacted to 
provide missing statistics such as standard deviations. We decided to change our methods for dealing with missing data due to the 
high percentage of drop-outs in some of the included studies. The original statistical analysis plan was to include these missing 
participants as treatment failures (i.e. they all developed cutaneous leishmaniasis); however, this would have resulted in very high 
prevalence of disease.
We did not assume that the people with missing data were treatment failures. In other words this meant that for some studies more 
than 50% of the participants would be assumed to have developed leishmaniasis, which was irrational. 
The analysis assumed that the people with missing data did not develop the disease (assuming none of the dropouts had events), 
which we think is the safest option to use. The other scenarios gave similar non-significant effects for individual study results in 
most cases.
We additionally compared the effect of allowing for different methods of imputations [62], to find if our assumptions were plausible.
For continuous outcomes, we were unable to allow for missing data in our analyses due to how the data were reported in the original 
papers, therefore we used data as presented in the original papers.
Assessment of heterogeneity: Statistical heterogeneity was assessed using I2 statistic. If substantial heterogeneity (I2>50%) existed 
between studies for the primary outcomes, reasons for heterogeneity, such as comparing the one-, two-, and three-dose regimens, and 
between adults and children would have been conducted. Additionally, meta-regression techniques would have been used to explore 
the relation between the length of the interval between the injections in the two- and three dose regimens and the efficacy of the 
vaccine. However, in this review there were insufficient numbers of studies included in the comparisons to allow statistical analysis.
Assessment of reporting biases: We had planned to test publication bias by the use of a funnel plot if adequate data had been 
available for similar types of interventions. But in this review, only a few studies were included in most comparisons, so funnel 
plots were not used.
Results 
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The electronic database searches identified a total of 408 studies, and three more studies were identified from other sources, 381 
articles remained after duplications were removed. We screened 381 references of which 362 were excluded based on titles and 
abstracts alone. The full text was sought for 19 references. Twelve studies (reported in 10 references) were included and a further nine 
references were excluded after reading the full text. For a further description of our screening process, see the study flow diagram.
Twelve RCTs (reported in 10 papers) were eligible for inclusion in the systematic review [35-37,51,63-67]. A total of 28,297 participants 
were included in these trials. Details of all the studies are listed in the Appendix tables.
The data for Antunes 1986a (1981 I) [51]; Antunes 1986b (1981 II) [51]; Antunes 1986c (1983) [51] are reported in one published 
paper but have been entered as three separate studies in this review. This is because the paper reports data for two separate trials 
that were carried out in 1981 and a third trial conducted in 1983. During the 1981 trial, group 1 went into the jungle from March to 
November for a total of 60 days, whereas group 2 stayed in the jungle for 23 days during the months of February, March and April. 
Thus, we included them as three individual trials as the populations were different.
In this review, we did not have any cross-over or internally controlled trials, but we did have one cluster randomised trial [65] among 
our included studies.
Setting: The studies were conducted in endemic countries including Iran [36,64-66], Brazil [51,65], Ecuador [35,63] and Colombia 
[67]; on Old World [36,37,64-66] and American, New World leishmaniasis [35,51,63,65,67]. The study durations were one year, 
2 years and more. All participants were healthy individuals living in endemic regions, likely to develop CL. The age range of the 
participants was wide, including young children, soldiers and adults up to 72 years and both genders. 
• UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) [36,37,51, 63-65,67],
• Center for Research & Training in Skin Diseases & Leprosy, TUMS [64,65],
• ‘Financiadora de Estudos e Projetos’ (F1NEP), ‘Superintendencia de Campanhas do Ministerio da Satide’ (SUCAM), the Pan 
    American Health Organization (PAHO), from ‘Conselho Nacional de Desenvolvimento Cientifico e Tecnologico’ (CNPq), 
   ‘Ministerio do Exercito’ (Comando Militar da Amazonia — CMA) [51],
• US Agency for International Development [35],
• fundacao de Amparo a Pesquisa do Estado de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil [CBB-562/02 and CBB-653/06]; 
  Conselho Nacional de Desenvolvimento Cientıfica e Tecnologica, Brasılia, Distrito Federal, Brazil [350200/1998-0], research 
  fellowships from CNPq [65],
• Universidad de Antioquia [67].
Participants were people from endemic areas with no previous history of leishmaniasis and in different age groups, including school 
children [36,64,66], army conscripts [51], rural populations [63,65], military base residents [37] and soldiers [67].
The interventions were single doses [36,37], double doses [35,51,63,65] or triple doses [64-67] of vaccines made from killed 
promastigotes, which were accompanied with BCG injections in eight studies [35-37,63-67].
Studies were selected based on the fact that the study reported the outcome of the incidence of cutaneous leishmaniasis in the population 
after a specified follow-up time. However, some of these studies had also reported LST (or Montenegro Skin Test (MNST)) [35-
37,63,64,66,67] and side effects [35-37,63-65,67]. The LST or the Montenegro Skin Test is used to diagnose cutaneous leishmaniasis. 
The test measures the delayed type hypersensitivity reactions to an intradermal injection of a suspension of killed promastigotes.
Nine studies were excluded because they did not meet the inclusion criteria and the reasons are provided below. A comprehensive list 
is available in the appendix. The reasons are listed below:
Design: From the 12 trials, nine had been published, and three [64-66] had not been published. All were randomised controlled 
clinical trials, and one was a cluster randomised trial [65].





Studies were funded by
Results of the search 
Included studies 
Excluded studies 
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• Studies were not a randomised controlled trial [32,52] 
• The occurrence rate of cutaneous leishmaniasis not reported (inoculation site not counted) [34,38,40,68-70].
• Articles about using the vaccine for treatment of cutaneous leishmaniasis after its presence and not about prevention [72].
Allocation (selection bias): All studies randomized their participants into the intervention and control groups; however, although 
sequence generation and allocation concealment was satisfactory for eight of the studies, four did not report details so the risk of bias 
was judged unclear [35,64,65].
Blinding (performance bias and detection bias): The level of detail about blinding of participants and personnel (performance bias) 
in the reporting varied but all studies except one were double blind and were assessed as low risk of bias. One trial [65] did not provide 
details about blinding of participants and personnel and was assessed to have an unclear risk.
Blinding of outcome assessors (detection bias) was only reported by three studies [36,37,63] which were considered at low risk of bias 
and the remaining studies were judged unclear risk of detection bias. 
Seven studies were rated as low risk of attrition bias. In the study by Sharifi 1998, there appeared to be no missing data. For Momeni 
1999, the important point about loss to follow-up is that the rate was similar between the intervention and control groups (30% versus 
28%), even though these rates are both high; therefore it is still valid to assume that none of these drop outs had the event. For Armijos 
2004, less than 80% completed the 2nd vaccine; however, we assumed that none of the dropouts had events so we did an ITT analysis 
based on the number randomized before the first vaccine as we think this is the more appropriate denominator to use.
Selective reporting (reporting bias): All of the studies were assessed to have an unclear risk of reporting bias. It did seem likely that 
there was selective reporting of the side effects as authors mentioned only some of the side effects and there was no identical list for 
reporting the side effects between studies. Selective reporting did not seem to be an issue in the main outcomes; however, no study 
protocols were available and so the possibility of reporting bias was unclear.
Other potential sources of bias: All studies were rated as unclear for other sources of bias. Three studies [64-66] were unpublished 
and were, therefore, not peer reviewed or refereed. We asked the authors about why they did not publish the studies. The author 
of Sharifi 2001 mentioned lack of time, although he did present the results in a conference. The author of Khamesipour 2000a and 
Khamesipour 2000b mentioned that the final reports were sent to the WHO and the results of these trials were later mentioned in 
two review papers [27,73].
The occurrence of Old World and American cutaneous leishmaniasis with any dose of vaccine versus no vaccination showed no 
significant differences after one year follow-up (RR 0.87, 95% CI 0.73 to 1.05; participants = 22,566; studies = 11, I²= 32%, NNT=355, 
Analysis 1.1.1). The 11 studies were: Antunes 1986a (1981 I); Antunes 1986b (1981 II); Antunes 1986c (1983); Armijos 1998; Armijos 
2004; Khamesipour 2000a; Khamesipour 2000b; Momeni 1999; Sharifi 1998; Sharifi 2001; and Velez 2005 (Figure 1).
Similarly at two years follow-up in Ecuador and Iran (RR 0.88, 95% CI 0.70 to 1.11; participants = 13,168; studies = 6, I²= 65%, 
NNT=155, Analysis 1.1.2), there was no significant difference in the occurrence of CL. The six studies were: Armijos 1998, Armijos 
2004, Khamesipour 2000a, Khamesipour 2000b, Momeni 1999, and Sharifi 1998.
An extremely high level of heterogeneity (I²= 90%) was detected between the three studies [64,65,66]; therefore, the results from the 
pooled analysis were likely to be misleading and are not reported. All three studies reported a RR for the occurrence of CL after two 
years follow-up, which were: RR = 1.02 (95% CI 0.81 to 1.28), RR = 0.20 (95% CI 0.1[64] to 0.39) [65] and RR = 0.84 (95% CI 0.63 to 
1.12) [66]; but only one of these was statistically significant [65].
Occurrence of cutaneous leishmaniasis at the end of one year, two years and more than two years.
Any dose of vaccine versus no vaccine
One year follow-up
Two years follow-up
More two years follow-up
Primary Outcome
Effects of interventions: 
Incomplete outcome data (attrition bias): All clinical trials had a follow-up rate above 80% except for three studies [35,63,64] which 
were judged to have a high risk of attrition bias. The risk in two studies was unclear [65,66].
There are two ongoing studies about this topic, currently underway in Iran [72,73].
Risk of bias in included studies 
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Figure 1: Comparison of using any dose of the vaccine versus 
no vaccine in occurrence of cutaneous leishmaniasis 
Up: at one year follow up
Down: at 2 years follow up
Two studies from Iran [36,37] looked at single doses of vaccine + BCG versus BCG alone (Figure 2).
Single doses of vaccine + BCG versus BCG alone
Figure 2: Comparison of using a single dose of the vaccine+BCG 
versus BCG alone in occurrence of cutaneous leishmaniasis 
Up: at one year follow up
Down: at 2 years follow up
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There was no significant differences in the occurrence of CL after one year follow-up (RR=0.83, 95% CI 0.42 to 1.62; participants = 
5947; studies = 2, I2 = 53%, NNT=10535, Analysis 2.1.1).
There was no significant differences in the occurrence of CL after 2 years of follow-up (RR=0.94, 95% CI 0.80 to 1.10; participants = 
5947; studies = 2, I2 = 0%, NNT=224, Analysis 2.1.2).
A pooled analysis was done for the studies that looked at two doses of the different types of vaccines versus no vaccine (no leishmaniasis 
vaccine) (Figure 3).
From studies conducted in Brazil and Ecuador after one year follow-up, there may be less CL in the group that was given two doses of 
the vaccine compared with the group not given any vaccine, but there is uncertainty about the result (RR=0.62, 95% CI 0.37 to 1.05; 
participants = 5620; studies = 5, I²= 34%, NNT=106, Analysis 3.1.1). The five studies were [35,51,63]. 
An extremely high level of heterogeneity (I2 = 83%) was detected between the two studies [35,63]; therefore, the results from the 
pooled analysis was likely to be misleading and a meta-analysis was not reported. One of the studies found a significant difference 
in occurrence of CL after two years follow-up in favour of the vaccine (RR=0.43, 95% CI 0.28 to 0.67) [35]; however, the other study 
found there may be an increase in CL in the group given the vaccine, although the results are very uncertain (RR=1.41, 95% CI 0.61 
to 3.29) [63].
One further study [65] assessed the effects at eight years, and found a significant difference in favour of two doses of vaccine versus 
placebo (phosphate buffer) (RR 0.19, 95% CI 0.10 to 0.38; participants = 5731; studies = 1, NNT=74, Analysis 3.1.2).
Four studies conducted in Iran and Colombia looked at three doses of vaccine plus BCG versus BCG alone (Figure 4).
One year follow-up
Two years follow-up
Two doses of vaccine versus no vaccine
One year follow-up
Two years follow-up
More than two years follow-up
Three doses of vaccine + BCG versus BCG alone
Figure 3: Comparison of using two doses of the vaccine versus no 
vaccine in occurrence of cutaneous leishmaniasis 
Up: at one year follow up
Down: at more than 2 years follow up
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There were no statistically significant differences in occurrence of CL after 2 years (RR 1.02, 95% CI 0.84 to 1.23; participants = 8404; 
studies = 3, I²= 0%, NNT=762, Analysis 4.1.2) in Khamesipour 2000a, Khamesipour 2000b, and Sharifi 2001.
There were no statistically significant differences in occurrence of CL after more than two years follow-up only in Iran (RR 0.94, 95% 
CI 0.78 to 1.14; participants = 6408; studies = 2, I²= 5%, NNT=228, Analysis 4.1.3) in Khamesipour 2000a, and Sharifi 2001.
Leishmanin skin test conversion rate (LST) at the end of one year, two years and greater than two years. Mild skin test reactions 
(indurations <5mm were regarded as negative and >5mm as positive).
The reason for the high heterogeneity among the results of different studies maybe due to the differences in the promastigote subtypes, 
the populations and the settings.
The results using different scenarios to analyze missing data show that even in different approaches for dealing with missing data, the 
pooled results are not statistically significant.
Two years follow-up
More than two years follow-up
Secondary Outcomes
There were no statistically significant differences in occurrence of CL after one year (RR 0.97, 95% CI 0.80 to 1.18; participants = 
10999; studies = 4, I2 = 1%, NNT=1036, Analysis 4.1.1) in Khamesipour 2000a, Khamesipour 2000b, Sharifi 2001, and Velez 2005.
One year follow-up
Figure 4: Comparison of using three doses of the vaccine+BCG 
versus BCG in occurrence of cutaneous leishmaniasis 
Up: at one year follow up
Middle: at 2 years follow up
Down: at more than 2 years follow up
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We completed an analysis of conversion rates (LST); however, in line with our protocol, we excluded papers which did not also report 
incidence rates of CL and, therefore, caution needs to be used when interpreting the findings for this outcome. Nevertheless, in 
trials where post-vaccination LST was measured, this evidence of immunogenicity induced by the vaccine was not carried over to a 
protective effect and this casts doubt on the merit of the vaccine-induced LST response as a correlate of immunity [27].
Three studies (n = 8322) reported results for LST, after one year follow-up [36,37,67], but pooling was not done due to extreme 
levels of heterogeneity between the studies (I2 = 98%; Analysis 1.2). Two studies, one from Iran (RR=1.68, 95%CI 1.41 to 2.01; 2310 
participants) [36] and the other from Colombia (RR=5.01, 95%CI 4.43 to 5.67; 2597 participants) showed that the vaccine significantly 
increased the proportion of participants with immunogenicity compared with no vaccine; whilst the third study from Iran [37] 
showed no significant difference (RR=0.88, 95%CI 0.61-1.25; 3415 participants) in LST rates between the groups.
In Armijos 1998 the Montenegro Skin Test (MNST) was used and it was measured at one month after vaccination, and thus these 
data were not included in the review. We could not add data for Armijos 2004, as although most outcomes were reported at the end 
of year one, two years, and later; the results for the LST were only reported at two months post vaccine. In Antunes 1986a (1981 I), 
Antunes 1986b (1981 II) and Antunes 1986c (1983) there was only LST data for the vaccine group and not the control, and thus 
was not included in the analysis. In Khamesipour 2000b, Khamesipour 2000a and Sharifi 2001 the LST results were not reported. In 
Mayrink 2013, participants with naturally positive LST were excluded and later the LST test was used in patients presenting lesions to 
confirm the diagnosis of ACL and it was not reported as a separate outcome.
Only seven studies reported side effects for these vaccines [35-37,63-65,67]. The side effects reported in these studies were ulceration, 
scars, pain, redness (erythema), induration, itching, swelling, lymphadenopathy and secretions at the site of injection (both in the 
vaccine and placebo group, but usually more severe in the vaccine group) and low grade fever and malaise. However, none of the 
studies reported side effects associated with the vaccine that was severe enough to stop the trial.
The exact number of these side effects was trivial or not reported in studies. Mortality and quality of life was not reported by any of 
the studies.
No studies reported LST data for the second year or longer.
Side effects of the vaccine
Local side effects, such as pain, redness, ulcer, lymph node swelling, itch and induration
When the results for all doses (one, two or three doses) of vaccine were compared with no vaccine, there was very low quality evi-
dence (See SoF table) of no significant difference between the groups with respect to incidence of CL after one year (participants = 
22566; studies = 11) or two years (participants = 13168; studies = 6). For more than two years there was significant heterogeneity 
between the results.
In this review we assessed the effects of vaccines in preventing the occurrence of cutaneous leishmaniasis. Twelve studies from four 
different countries were included, with a total of 28,297 participants. Studies were mainly well designed RCTs with high sample siz-
es. We classified the trials and reported them according to the dosage of vaccines and the intervention used in the control groups.
Summary of main results 
Different regimens were used in the control arm, including BCG [35-37,63-67] and in four studies phosphate buffer 7.4 [51].
Discussion 
For the secondary outcomes of LST, although there were three studies which reported this outcome, there was significant heter-
ogeneity between the results and we were unable to pool the results. The evidence was low quality. Two studies found the vaccine 
significantly increased the proportion of participants with immunogenicity as compared to no vaccine and one found no signifi-
cant difference. However, this evidence of immunogenicity induced by the vaccine (or otherwise) did not appear to be associated 
with a protective effect against the incidence of cutaneous leishmaniasis in those studies.
Side effects of the vaccine were mentioned by some of the studies, but none were severe enough to stop the trial. Mortality and 
quality of life were not reported by any of the studies included in this review.
When the results were subgrouped by the number of doses of vaccine given, for a single dose of vaccine, there was low quality ev-
idence (See SoF table) of no significant difference in the incidence of CL between the treatment arms at one year (RR 0.83, 95% CI 
0.42 to 1.62; participants = 5947; studies = 2) and at two years (RR 0.94, 95% CI 0.80 to 1.10; participants = 5947; studies = 2). All 
participants included in both treatment groups of all studies also received a BCG. Results for more than two years were not available.
In studies in which two doses of vaccine were given, there was very low quality evidence (See SoF table) that there may have been 
a reduction in CL in the groups receiving the vaccine compared with no vaccine at one year, but the results are uncertain (partic-
ipants = 5620; studies = 5). The results at two years were too heterogeneous to pool. At more than two years there was one study 
with unclear risk of bias which showed a significant reduction in the incidence of CL at eight years.
Annex Publishers | www.annexpublishers.com                    
 
Volume 1 | Issue 1
Journal of Vaccines & Vaccination Studies 
 
14
When three doses of vaccine were given, there was very low quality evidence (See SoF table) of no significant difference in the inci-
dence of CL between the treatment arms at one year ( participants = 10999; studies = 4), at two years (participants = 8404; studies 
= 3) or at more than two years (participants = 6408; studies = 2). All participants included in both treatment groups of all studies 
also received BCG.
Although we did not detect any publication bias, but it is possible that there are unpublished studies. Only a few studies were in-
cluded in most comparisons so funnel plots were not used; this also limits the possibility of detecting publication bias.
Despite the relatively high participant numbers in the studies, the rate of incidence of CL was relatively low which resulted in 
increased imprecision. There were wide confidence intervals which increases the uncertainty of findings. In these cases, where 
imprecision was detected and was judged to be serious, the evidence was downgraded.
The quality of evidence was affected by a number of issues including poor methodological reporting, imprecision and suspicion of 
publication bias. Although the studies were relatively large with respect to number of participants included, many did not report 
methods very well and were rated as unclear in a number of different risk of bias domains.
Although both genders and different age groups were evaluated in these studies, but studies were performed in only 4 countries 
and therefore the results may not be globally generalizable and applicable. The heterogeneity in some outcomes was too high and 
we were not able to pool the results, which also show that the populations under study and the promastigotes have different char-
acteristics and more studies are needed.
Only seven of the included studies reported side effects. The reported side effects were limited and related mainly to BCG. Only 
in some studies was LST performed, and authors have provided limited information about these outcomes. We also might bear in 
mind that the vaccines used in different studies were not identical and therefore probably have different side effects anyway. No 
study investigated quality of life or mortality.
The impact of the bacille Calmette-Guerin vaccine (BCG) alongside the vaccine for leishmaniasis in under question in these arti-
cles. It is thought that injection of bacille Calmette-Guerin vaccine (BCG) significantly increases cell mediated immune response 
and this may reduce the incidence of leishmaniasis infection [27]. Therefore in a clinical trial , BCG may not be a true placebo, and 
may dilute the true effect of the vaccine [27,73].
Overall, there was a low rate of participant drop-out from the trials. There were only three studies [35,63,64] with follow-up rates 
under 80%. However, the authors have reasoned that the remaining population that was analysed in the study had similar charac-
teristics and, therefore, the bias introduced was trivial.
Overall completeness and applicability of evidence 
Quality of the evidence 
The quality of evidence for the outcomes was generally very low, or low in the results of this review. 
Findings were relatively consistent, and heterogeneity (I² > 80%) was found in only two analysis. One for the occurrence of cuta-
neous leishmaniasis at more than two years follow-up (at the any vaccine versus no vaccine group) and at the two dose vaccine 
versus no vaccine at 2 years follow-up.
Potential biases in the review process 
We were not able to compare side effects between adults and children because the side effects had not been reported separately for 
children and adults in studies.
We did not assess the effect of the length of interval between the doses in the two and three-dose regimen on the preventive effect 
of the vaccine, because the number of studies was too low to a meta-regression.
We were not able to compare the efficacy of three-dose, two-dose and one-dose regimens, as none were significant except the two-
dose regimen after more than 2 years follow-up and this was based on just one study with very low quality.
Our units of analysis are different from what was planned in the protocol because after extracting the real data the proposed units 
of data analysis were not suitable. 
We decided to change our methods for dealing with missing data due to the high percentage of drop-outs in some of the included 
studies [37,63,66]. The original statistical analysis plan was to include these missing participants as treatment failures (i.e. they all 
developed cutaneous leishmaniasis); however, this would have resulted in a very high prevalence of disease which was irrational 
and unrealistic. Therefore we did not do this.
However, we do not think any of these issues has caused a serious bias in the review process. 
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A previous narrative review concluded that first generation vaccines showed a limited efficacy, and at present there is no vaccine 
available against leishmaniasis [27]. A meta-analysis also indicated that the whole-parasite vaccines tested until that time, did not 
induce significant protection against human leishmaniasis [73]. The result of this current review is in line with previous reviews. 
The studies used in these previous reviews were all included in this currect review.
Agreements and disagreements with other studies or reviews 
Our results also showed in some trials where post vaccination LST was measured after a year the responses were larger in the vac-
cine group. Other reviews have also cast doubt on the merit of the vaccine induced LST response as a predictor of immunity [27]. 
On the other hand there are reports that there is a strong correlation between LST conversion and protection after recovery from 
the disease [30]; but, the immunological implication of the LST response also depends on the factors and conditions that gave rise 
to it [27]. In some trials, the incidence rate was significantly lower in those vaccinated subsets with LST conversion from zero to 5 
mm and more [51]. Some investigators observed a lower incidence of leishmaniasis in the subset of those in the vaccinated group 
whose Leishmanin Skin Test (LST) had converted (from an induration of < 5mm to > 5mm) after vaccination [73].
LST is highly variable and not a precise tool of correlation with protection and it is more related to exposure than protection 
[64,65] (unpublished data). At the time of design of the trials, BCG was the only choice with a high safety profile in people. It was 
assumed to induce a Th1 response only as an indicator of previous exposure to leishmaniasis. This could have led to misclassi-
fication of some individuals with previous exposure and immunity as unexposed (instead of exposed) [73], but this would have 
allowed their inclusion in both arms of the clinical trial. However, some authors [73] believe that the protective efficacy of the 
vaccine may have been underestimated because of this misclassification.
It is thought that injection of Bacille Calmette-Guerin vaccine (BCG) significantly increases the cell mediated immune response 
by an increase in Leishmanin skin test (LST) positivity. Some researchers [27] have observed that the LST conversion due to vac-
cination is associated with reduced incidence of leishmaniasis infection. Therefore in a clinical trial setting, the use of BCG in the 
control arm may not constitute a true placebo, since BCG induces LST conversion in individuals in the control arm and may dilute 
the true effect of the vaccine [27,75].
These results raise the question about the impact of the Bacille Calmette-Guerin vaccine (BCG) alongside the vaccine for leish-
maniasis. In this review eight of the 12 included studies gave participants in both arms of the study some level of BCG vaccine 
[35-37,63-67]. In Ecuador, Armijos used BCG (about 1/2 the dose normally used for vaccination against tuberculosis) in both his 
trials [35,63]. In Momeni 1999 and Sharifi 1998, a 1/10 of the normal dose (used in vaccination against tuberculosis) was used in 
leishmaniasis vaccine trials. In all prophylactic clinical trials of killed parasites plus BCG, BCG alone was used in the control arm 
and this was to preserve blinding in the trials as BCG may leave a scar similar to leishmaniasis.
Second generation vaccines were evaluated in phase 1 and 2 clinical trials [74], but were not included in this review. It is likely 
that by the time this review is updated, second generation vaccines will have been assessed in well-designed randomised double 
blinded studies and we will be able to include them in this review.
However, most authors think that although trials with first generation vaccines did not result in identification of an efficacious 
vaccine, they did show the safety of these vaccines. These trials have made a significant contribution to improving the quality of 
vaccine investigation in the countries where they were conducted, and where leishmaniasis is endemic. These include training 
personnel and identifying particular issues related to the development of vaccines against leishmaniasis [27].
The results of this review, current to October 2017, show that there is generally low or very low quality evidence about the effect of 
current vaccine on preventing cutaneous lesishmaniasis (CL). Serious vaccine side effects were not reported within the trials. No 
information about quality of life or mortality is available.
For any dose of vaccine versus no Leishmaniasis vaccination in the pooled analysis, after one year and after two years follow up no 
significant results in favor of the vaccine were seen. Among 3 studies with more than two years follow up, pooling of the results 
was not possible and only one of these three studies showed a significant protective effect. All were based on low quality evidence.
Three studies reported results for LST, after one year follow-up, but pooling was not possible. Two studies showed that the vaccine 
significantly increased the proportion of participants with positive LST compared with no vaccine; whilst the third study showed no 
significant effect. There was no data about more than one-year follow-up for this outcome and the available evidence was low quality.
There was no significant effect in favor of a single dose of vaccine plus the bacille Calmette-Guerin vaccine (BCG), versus BCG alone 
after one year follow up or after 2 years of follow up based on some low quality evidence.
Implications for practice 
Authors' conclusion
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In using two doses of vaccine versus no Leishmaniasis vaccine, no significant effect was seen in favor of the vaccine after one year 
follow up. Pooled analysis was not done for the two studies with two years of follow up. One of the studies found a significant effect 
in favour of the vaccine; however, the other study found no effect. There was a statistically significant effect, in favor of the vaccine 
after more than 2 years follow up, but this was based on only one study. The quality of evidence in these studies was all very low.
Three doses of vaccine plus BCG in comparison to BCG alone did not show a significant effect after one year, two years or more than 
two years either, but the quality of evidence was very low.
There was no conclusive evidence that the number of doses of leishmaniasis vaccine had an impact on the occurrence of CL, com-
pared with no vaccine.
Future studies should be conducted with stronger methodology and less bias. Studies have to be clear in regard to random sequence 
generation and allocation concealment. Blinding of all patients and personnel and outcome assessors should be done adequately. 
Attrition bias should be kept to a minimum and researchers should plan to follow all individuals. Researchers should refrain from 
selective reporting. Side effects should be reported thoroughly and by numbers. Quality of life related to the vaccine should also be 
evaluated in future studies. 
• How effective is the BCG vaccine in preventing cutaneous leishmaniasis? It would be interesting if it was possible to compare the 
   incidence in BCG vaccinated and not vaccinated individuals.
• Is the two dose vaccine the most effective among the first generation of vaccines?
• How effective are the second and third generation vaccines?
• How much will an effective vaccine cost consumers?
• What are the side effects of an effective vaccine?
• Is it worthwhile vaccinating everyone in endemic areas?
There is hope that the second or third generation of vaccines which are currently being studied might be effective in preventing CL.
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